11/13/2024 | Press release | Distributed by Public on 11/13/2024 08:03
| | |
Public Offering
Price(1) |
| |
Underwriting
Discount(2) |
| |
Proceeds(1)
|
| |||||||||
Per note
|
| | | | % | | | | | | % | | | | | | % | | |
Total
|
| | | $ | | | | | $ | | | | | $ | | | |||
Per note
|
| | | | % | | | | | | % | | | | | | % | | |
Total
|
| | | $ | | | | | $ | | | | | $ | | | |||
Per note
|
| | | | % | | | | | | % | | | | | | % | | |
Total
|
| | | $ | | | | | $ | | | | | $ | | | |||
Per note
|
| | | | % | | | | | | % | | | | | | % | | |
Total
|
| | | $ | | | | | $ | | | | | $ | | | |
|
Barclays
|
| |
BofA Securities
|
|
| | |
Page
|
| |||
About This Prospectus Supplement
|
| | | | S-ii | | |
Where You Can Find More Information
|
| | | | S-iii | | |
Summary
|
| | | | S-1 | | |
Risk Factors
|
| | | | S-5 | | |
Forward-Looking Statements
|
| | | | S-7 | | |
Use of Proceeds
|
| | | | S-8 | | |
Capitalization
|
| | | | S-9 | | |
Description of the Notes
|
| | | | S-10 | | |
United States Federal Income Tax Considerations
|
| | | | S-22 | | |
Underwriting
|
| | | | S-26 | | |
Legal Matters
|
| | | | S-32 | | |
Experts
|
| | | | S-32 | | |
| | |
Page
|
| |||
About This Prospectus
|
| | | | 1 | | |
Where You Can Find More Information
|
| | | | 1 | | |
Forward-Looking Statements
|
| | | | 2 | | |
Gilead Sciences, Inc.
|
| | | | 2 | | |
Risk Factors
|
| | | | 3 | | |
Use of Proceeds
|
| | | | 3 | | |
Description of Securities
|
| | | | 3 | | |
Description of Debt Securities
|
| | | | 3 | | |
Description of Capital Stock
|
| | | | 12 | | |
Description of Depositary Shares
|
| | | | 14 | | |
Description of Warrants
|
| | | | 14 | | |
Description of Subscription Rights
|
| | | | 15 | | |
Description of Stock Purchase Contracts and Stock Purchase Units
|
| | | | 16 | | |
Plan of Distribution
|
| | | | 16 | | |
Legal Matters
|
| | | | 17 | | |
Experts
|
| | | | 18 | | |
| | |
As of September 30, 2024
|
| |||||||||
(in millions, except per share amounts)
|
| |
Actual
|
| |
As Adjusted
|
| ||||||
Cash and cash equivalents
|
| | | $ | 5,037 | | | | | $ | | | |
Long-term debt: | | | | | | | | | | | | | |
3.500% Senior Unsecured Notes due February 2025
|
| | | | 1,750 | | | | | | | | |
3.650% Senior Unsecured Notes due March 2026
|
| | | | 2,746 | | | | | | | | |
2.950% Senior Unsecured Notes due March 2027
|
| | | | 1,248 | | | | | | | | |
1.200% Senior Unsecured Notes due October 2027
|
| | | | 748 | | | | | | | | |
1.650% Senior Unsecured Notes due October 2030
|
| | | | 995 | | | | | | | | |
5.250% Senior Unsecured Notes due October 2033
|
| | | | 993 | | | | | | | | |
4.600% Senior Unsecured Notes due September 2035
|
| | | | 994 | | | | | | | | |
4.000% Senior Unsecured Notes due September 2036
|
| | | | 743 | | | | | | | | |
2.600% Senior Unsecured Notes due October 2040
|
| | | | 989 | | | | | | | | |
5.650% Senior Unsecured Notes due December 2041
|
| | | | 996 | | | | | | | | |
4.800% Senior Unsecured Notes due April 2044
|
| | | | 1,737 | | | | | | | | |
4.500% Senior Unsecured Notes due February 2045
|
| | | | 1,735 | | | | | | | | |
4.750% Senior Unsecured Notes due March 2046
|
| | | | 2,223 | | | | | | | | |
4.150% Senior Unsecured Notes due March 2047
|
| | | | 1,730 | | | | | | | | |
2.800% Senior Unsecured Notes due October 2050
|
| | | | 1,479 | | | | | | | | |
5.550% Senior Unsecured Notes due October 2053
|
| | | | 988 | | | | | | | | |
% Senior Unsecured Notes due offered hereby
|
| | | | - | | | | | | | | |
% Senior Unsecured Notes due offered hereby
|
| | | | - | | | | | | | | |
% Senior Unsecured Notes due offered hereby
|
| | | | - | | | | | | | | |
% Senior Unsecured Notes due offered hereby
|
| | | | - | | | | | | | | |
Total senior unsecured notes
|
| | | | 22,094 | | | | | | | | |
Liability related to future royalties
|
| | | | 1,155 | | | | | | | | |
Total long-term debt
|
| | | | 23,249 | | | | | | | | |
Stockholders' equity: | | | | | | | | | | | | | |
Preferred stock, $0.001 par value; 5 shares authorized; none outstanding
|
| | | | - | | | | | | | | |
Common stock, $0.001 par value; shares authorized of 5,600 at September 30, 2024; shares issued and outstanding of 1,246 and 1,246, respectively, at September 30, 2024(1)
|
| | | | 1 | | | | | | | | |
Additional paid-in capital
|
| | | | 7,327 | | | | | | | | |
Accumulated other comprehensive income
|
| | | | 73 | | | | | | | | |
Retained earnings
|
| | | | 11,073 | | | | | | | | |
Total Gilead stockholders' equity
|
| | | | 18,475 | | | | | | | | |
Noncontrolling interest
|
| | | | (84) | | | | | | | | |
Total stockholders' equity
|
| | | $ | 18,390 | | | | | $ | | | |
Total capitalization
|
| | | $ | 41,639 | | | | | $ | | | |
Underwriters
|
| |
Principal Amount
of Notes |
| |
Principal Amount
of Notes |
| |
Principal Amount
of Notes |
| |
Principal Amount
of Notes |
| ||||||||||||
Barclays Capital Inc.
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | ||||
BofA Securities, Inc.
|
| | | | | | | | | | | | | | | | | | | | | | | | |
Total
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | |
| | |
Payable by us
|
| |||||||||||||||||||||
| | |
Notes
|
| |
Notes
|
| |
Notes
|
| |
Notes
|
| ||||||||||||
Per Note
|
| | | | % | | | | | | % | | | | | | % | | | | | | % | | |
Total
|
| | | $ | | | | | $ | | | | | $ | | | | | $ | | | |
| | |
Page
|
| |||
About This Prospectus
|
| | | | 1 | | |
Where You Can Find More Information
|
| | | | 1 | | |
Forward-Looking Statements
|
| | | | 2 | | |
Gilead Sciences, Inc.
|
| | | | 2 | | |
Risk Factors
|
| | | | 3 | | |
Use of Proceeds
|
| | | | 3 | | |
Description of Securities
|
| | | | 3 | | |
Description of Debt Securities
|
| | | | 3 | | |
Description of Capital Stock
|
| | | | 12 | | |
Description of Depositary Shares
|
| | | | 14 | | |
Description of Warrants
|
| | | | 14 | | |
Description of Subscription Rights
|
| | | | 15 | | |
Description of Stock Purchase Contracts and Stock Purchase Units
|
| | | | 16 | | |
Plan of Distribution
|
| | | | 16 | | |
Legal Matters
|
| | | | 17 | | |
Experts
|
| | | | 18 | | |